New developments in women and AIDS research.
D017088:AIDS-Related Opportunistic Infections; D020008:Delavirdine; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000502:physiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019247:HIV Wasting Syndrome / Q000150:complications / Q000503:physiopathology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D019888:Nelfinavir; D010879:Piperazines / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D011374:Progesterone / Q000502:physiology; D013451:Sulfonic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D004967:Estrogens; D017320:HIV Protease Inhibitors; D007211:Indoles; D007546:Isoquinolines; D010879:Piperazines; D013451:Sulfonic Acids; D015215:Zidovudine; D011374:Progesterone; D020008:Delavirdine; D019888:Nelfinavir